EsoCap AG announced today that the data from the ACESO Phase II study comparing ESO-101 to placebo for the treatment of eosinophilic esophagitis will be presented as part of an abstract session at the upcoming United Gastroenterology Week (UEGW) being held from October 12-15, 2024, in Vienna, Austria.
“We are thrilled that the clinical data from the ACESO Phase II study in esophageal esophagitis (EoE) will be presented in an abstract session at this leading gastroenterology meeting by Dr Alfredo J. Lucendo, Department of Gastroenterology, Hospital General de Tomelloso, Spain, and coordinating principal investigator of the ACESO study,” said Isabelle Racamier, CEO of EsoCap. “The results of the study showed that the primary endpoint was met with a statistically significant reduction of the peak eosinophil count (p=0.0318) compared to placebo. The ACESO study represents an important milestone in the development of our unique application platform for the treatment of esophageal diseases. With our lead product ESO-101, we have demonstrated that the EsoCap system can provide long-lasting, targeted topical delivery of the glucocorticosteroid mometasone furoate.”
The oral presentation will be part of abstract session:
Oesoniphilic esophagitis
Title: A novel delivery system for topical esophagitis treatment with mometasone furoate: results of the phase 2, randomized, double-blind, placebo-controlled ACESO trial
Presentation number: OP209
Date & time: October 15th at 11:54 in room Lehar 3
Presenter: Alfredo J. Lucendo (Spain)
